Astria Therapeutics to Present at Society for Investigative Dermatology Meeting

BOSTON-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical organization committed to creating transformative treatments for allergic and immunological conditions, has announced its participation in the Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas, scheduled for May 16, 2024. During this event, the company will present data regarding their preclinical candidate, STAR-0310.

Dr. Chunxia Lily Zhao, who serves as the Director of Antibody Discovery at Astria Therapeutics, is set to present a poster entitled “Preclinical Pro STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.” This presentation will occur during the Pharmacology and Therapeutic Development Select E-Poster Discussions on May 16, 2024, at 5:00pm CDT.

Astria Therapeutics is dedicated to developing medicinal solutions that significantly improve the lives of patients and families dealing with allergic and immunological diseases. The company's flagship program is STAR-0215, a monoclonal antibody inhibitor targeting plasma kallikrein, currently in clinical development for the treatment of hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody that serves as an OX40 antagonist, in preclinical development aimed at treating atopic dermatitis.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!